In the phase 3 RASolute 302 trial, oral KRAS inhibitor daraxonrasib nearly doubled median overall survival to 13.2 months in pancreatic cancer.
Paul Oberstein, MD
Advertisement
Articles by Paul Oberstein, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Zidesamtinib for Pretreated ROS1-Positive NSCLC
2
Study Reports 10-Year Outcomes of Focal Therapy for Prostate Cancer
3
Nurses Lead the Way in the New Era of Chronic Lung Cancer Care
4
FDA Grants Tentative Approval to Generic Olaparib Tablets
5